Leonard Post, Ph.D.

Cybrexa Scientific Advisor

Dr. Post has over 30 years of experience with all stages of drug development, from early discovery through FDA approval, with a particular focus on oncology and genetic diseases. Dr. Post was a founder and CSO of LEAD Therapeutics, which led to the discovery of Talazoparib (BMN-673), which was later acquired by BioMarin Pharmaceuticals, where he then served as the Chief Scientific Officer. Previously, he served as Senior Vice President of Research and Development for Onyx Pharmaceuticals from 2000 to 2006. In this role, he was responsible for the co-development of Nexavar through to FDA approval for renal cancer, and until 2004 also led Onyx’s oncolytic virus clinical program. Dr. Post received a B.S. in Chemistry from the University of Michigan and a Ph.D. in Biochemistry from the University of Wisconsin, Madison. Dr. Post is now the CSO of Vivace Therapeutics, anĀ oncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need.

 

5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731